Compugen announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, after 6 years with Compugen. Michelle joined Compugen in October 2023 as Vice President of Clinical Development. Most recently Michelle was the Chief Medical Officer of 1 E therapeutics Ltd., a drug development company, creating a novel class of programmable oligonucleotide therapeutics and Aummune Therapeutics Ltd., a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CGEN:
- Compugen to receive $10M milestone payment from AstraZeneca
- Biotech Alert: Searches spiking for these stocks today
- Compugen spikes after deal with Gilead for anti-tumor drug
- Compugen spikes 180% on $848M deal with Gilead for anti-tumor drug
- Compugen eligible to receive $10M payment upon dosing of AstraZeneca trial
